ASH17: Benefit of Gilead’s CAR-T remains durable over longer term – BioPharma Dive
|
ASH17: Benefit of Gilead's CAR–T remains durable over longer term
BioPharma Dive Updated results from a pivotal study of Gilead Sciences Inc.'s CAR–T therapy Yescarta offers new proof of the treatment's benefit over the longer term, suggesting those patients who go into remission are likely to remain so more than one year after … |
